This Phase 2 trial tests whether the oral drug gilteritinib works better than midostaurin for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-mutated AML). All 181 participants also receive standard chemotherapy. The goal is to see which drug leads to more …
Phase: PHASE2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC